Here is the design of a clinical trial:

Official Title: A Phase II Randomized Controlled Trial of Exercise in Prostate Cancer Patients Undergoing Active Surveillance

Included conditions:
- Prostate Cancer

Study Armgroups:
- {'label': 'Exercise Group', 'type': 'EXPERIMENTAL', 'description': 'Supervised high-intensity aerobic interval training (HIIT) during active surveillance', 'interventionNames': ['Behavioral: High-intensity aerobic interval training (HIIT)']}
- {'label': 'Usual Care Group', 'type': 'NO_INTERVENTION', 'description': 'The usual care group will be provided with standard active surveillance medical care.'}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'High-intensity aerobic interval training (HIIT)', 'description': 'A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals', 'armGroupLabels': ['Exercise Group']}

Primary Outcomes:
- {'measure': 'Changes of Peak Oxygen Consumption (VO2peak)', 'description': 'VO2peak is a measure of cardiopulmonary fitness and a powerful surrogate outcome for cancer-specific and overall survival. VO2peak will be defined as the highest oxygen-uptake value recorded during the test and quantified where participants reach a plateau in oxygen consumption, which will be expressed as relative to body mass (i.e., ml O2·kg-1·min-1).', 'timeFrame': 'At baseline and 12-week (postintervention)'}

Please estimate the sample size based on the assumption: 
Two-tailed alpha <0.05, 80% power, <10% dropout rate.
Sample size
        A sample size of 60 participants (30 per group) provides 80% power using a two-tailed alphaÂ <0.05âto detect a clinically meaningful between-group difference of 1-metabolic equivalent task (1-MET; 3.5âmL/kg/min) on our primary outcome of VO2peak, assuming a SD of 5.6âmL/kg/min and adjustment for baseline value and other prognostic covariates. It will also be sufficient for detecting differences in our secondary biomarkers and patient-reported outcomes.51 Considering a potential dropout rate ofÂ <10% based on our previous exercise oncology trials,52â55 a total of 66 participants (33 per group) will be randomised. This power will also be sufficient for detecting differences in our secondary biomarkers and patient-reported outcomes if the effects are moderate (ie, a standardised effect size of dâ¥0.6âapproximately). This power is not sufficient for detecting potentially meaningful differences in any of the exploratory clinical outcomes. Given that the purpose of this phase II trial is to inform larger phase II and III trials, the patient-reported and clinical outcomes will also be interpreted for potential clinical significance based on the direction and magnitude of numerical differences.